Aldevron Breakthrough Blog

Aldevron Honored by Goldman Sachs for Entrepreneurship

Michael Chambers, Founder and CEO, Among 100 Most Intriguing Entrepreneurs at 2018 Builders + Innovators Summit

Goldman Sachs (NYSE:GS) is recognizing Aldevron CEO and Founder Michael Chambers as one of the 100 Most Intriguing Entrepreneurs at the 2018 Builders + Innovators Summit in Santa Barbara, California.Goldman SachsGoldman Sachs selected Chambers as one of 100 entrepreneurs from multiple industries to be honored at the three-day event. Founded in 1998, Aldevron supplies plasmid DNA and gene editing enzymes to biopharmaceutical researchers developing advanced gene-based medicines. Aldevron also provides recombinant biological products for veterinary and agriculture applications.

“My colleagues and I are honored by this award,” said Michael. “It is the highest privilege to serve our clients who are leading a biotech revolution that is curing disease and helping to feed the world.” He added that Aldevron’s mission has remained unchanged for 20 years: to improve lives through innovative partnerships and scientific excellence.

Aldevron products are key components in clinical and commercial gene therapies. The company has locations in North Dakota, Wisconsin, and Germany, and has grown organically and through acquisition. Aldevron recently opened the first building on its new 10-acre campus in Fargo, North Dakota. The 70,000 square-foot structure is the largest plasmid DNA GMP manufacturing facility in the world.

“A dynamic economy depends on dynamic entrepreneurs who disrupt industries and occasionally give birth to entirely new sectors,” said David M. Solomon, Chief Executive Officer of Goldman Sachs. “The purpose of Builders + Innovators is to support emerging leaders in their quests to innovate faster in order to grow their ideas. We are pleased to recognize Michael Chambers as one of the most intriguing entrepreneurs of 2018.”

For more than 150 years, Goldman Sachs has been advising and financing entrepreneurs as they launch and grow their businesses. In addition to honoring 100 entrepreneurs, the Summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About the author

Latest posts

James Brown, Ph.D.

James Brown, Ph.D.

James Brown has over 25 years of biotechnology industry experience, and has spent the last decade in gene and cell therapy. In 2015 he joined Aldevron where he serves as Vice President, Corporate Development and Chief of Staff. His responsibilities include developing and implementing strategies for expanding Aldevron’s products and services. In this capacity he heads the product management function, which expands existing product features and develops new products. As Chief of Staff Brown works with the CEO to execute on his strategic priorities. Prior to joining Aldevron, Brown was Vice President, Technical Operations, at REGENXBIO Inc., a gene therapy company. In this role he was responsible for contract manufacturing, vendor management, operations, quality assurance and biological reagent sales. Prior to REGENXBIO Dr. Brown served in roles of increasing responsibility in operations and quality assurance at MedImmune, Meso Scale Discovery and IGEN International, Inc. Brown holds a Ph.D. in chemistry from Stanford University and a B.S. in chemistry from Butler University.

Topics: History